Business
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a leader in the development of novel bispecific antibodies ...
About this update from Aptevo Therapeutics Inc.
[{"type":"text","content":"Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action","length":104,"tagName":"p"},{"type":"text","content":"SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a leader in the development of novel bispecific antibodies for cancer treatment, based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies provided an overview of solid tumor anti-cancer compound APVO603, currently in preclinical development for the treatment of solid tumors. APVO603 is a novel bispecific antibody designed to enhance anti-tumor immune responses through dual targeting of 4-1BB (CD137) and OX40 (CD134), two key co-stimulatory receptors involved in T cell and NK cell activation.","length":605,"tagName":"p"},{"type":"text","content":"APVO603 is part of Aptevo's solid tumor anti-cancer pipeline and represents a significant step forward in leveraging the company's proprietary ADAPTIR® platform to develop safer and more effective immuno-oncology therapies.","length":231,"tagName":"p"},{"type":"text","content":"Targeted Immune Activation for Solid TumorsAPVO603 is designed to activate the costimulatory 4-1BB and OX40 pathways in the tumor microenvironment, leading to enhanced T cell expansion, survival, and cytotoxic function while avoiding systemic toxicity. This targeted immune activation could overcome immune suppression in solid tumors, a major challenge in cancer immunotherapy.","length":379,"tagName":"p"},{"type":"text","content":"Preclinical studies have shown that APVO603:","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Enhances T cell and NK cell proliferation and tumor lysis, while maintaining a favorable safety profile and inhibiting immune exhaustion","length":136,"tagName":"p"}]},{"val":[{"type":"text","content":"Induces a robust anti-tumor response in preclinical tumor models, suggesting strong therapeutic potential","length":105,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":241,"olType":false},{"type":"text","content":""We are excited about the potential of APVO603 to enhance the potency of T cells and NK cells while addressing the limitations of current therapies for solid tumors," said Michelle Nelson, PhD, Director of Immunobiology at Aptevo. "Our preclinical find...